Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review
NHSC
Record ID 32005000258
English
Authors' objectives:
This study aims to assess the potential for future impact of temsirolimus for locally advanced and metastatic breast cancer
Authors' recommendations:
Temsirolimus (CCI-779) inhibits the protein mTOR kinase and prevents cell division and tumour growth. It is currently in phase III clinical trials in combination with letrozole for the first-line treatment of postmenopausal women with oestrogen and/or progesterone receptor positive locally advanced or metastatic (stage III/IV) breast cancer. Preliminary phase II results in combination with letrozole show objective response rates of between 23% and 67% for combination therapy at various doses and intervals, compared to 30% for letrozole monotherapy.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Neoplasm Metastasis
- Breast Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.